Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Plasfer S R L currently maintains 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This activity is situated within 1 distinct art unit, showing a narrow technical focus for the company's current patent applications. The prosecution is managed by 1 distinct examiner, which limits the variety of examiner interactions the company must navigate at this time. This structure reflects a specialized technological development path.
The busiest examiner identified is LIPPOLIS, ALEXANDRA ROSE, who is responsible for 1 pending office action. This 1 action constitutes the entirety of the pending workload for the portfolio. With 1 distinct examiner and 1 distinct art unit, the prosecution path is direct. Practitioners working on this portfolio in the Biotechnology & Pharmaceuticals sector can dedicate their full attention to the specific preferences and history of LIPPOLIS, ALEXANDRA ROSE. This eliminates the need to reconcile examiner behaviors across multiple distinct examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIPPOLIS, ALEXANDRA ROSE | 1 | 46.9% | +59.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681188 | PLATELETS TRANSFECTED WITH SIRNA AND THE THERAPEUTICS USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18681188 | PLATELETS TRANSFECTED WITH SIRNA AND THE THERAPEUTICS USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18681188 | PLATELETS TRANSFECTED WITH SIRNA AND THE THERAPEUTICS USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | 1653 | §103§112 | Non-Final OA | — | Pending | Feb 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial